5 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 5 of 5 clinical reviews.
A critical analysis of the MAESTRO-NASH trial's enrollment biases, follow-up duration, generalizability gaps, statistical caveats, and conflict-of-interest considerations for resmetirom in MASH.
A deep-dive into MAESTRO-NASH follow-up and extension data for resmetirom, covering durability of histological response, emergent safety signals, and what long-term outcomes look like beyond the original 52-week results.
A detailed breakdown of the MAESTRO-NASH trial results for resmetirom in MASH, covering primary and secondary endpoints, effect sizes, confidence intervals, subgroup analyses, and response distribution.
A deep-dive into the MAESTRO-NASH phase 3 trial of resmetirom (Rezdiffra) for MASH with liver fibrosis, covering methodology, histological endpoints, safety data, and clinical implications.
Deep-dive into the MAESTRO-NASH trial of resmetirom for MASH: how FDA approval reshapes prescribing, which guidelines updated, and what clinicians should know beyond the abstract.